Cognivia CEO, Dominique Demolle, to Speak at Panel Discussion on Innovative Placebo Response Analysis in CNS Trials
Cognivia is thrilled to announce that Dominique Demolle, CEO of Cognivia, has been cordially invited to participate in…
News
News
News
Dominique Demolle to Unveil Cognivia AI-powered Innovations at DPharm Conference
Dominique Demolle, CEO of Cognivia, is set to deliver a captivating presentation at the upcoming DPharm conference which is scheduled for…
News
What the FDA’s Final Guidance on Covariates Means for Fighting the Placebo Response in RCTs: Our Article Published in ACRP Journal
The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.
News
Covariate Adjustment in Randomized Clinical Trials Based on Latest FDA Guidance: Application to composite covariates
In May 2023, the FDA has unveiled its definitive guidance titled “Adjusting for Covariates in Randomized Clinical Trials (RCT) for Drugs…
News
Webinar: Patient Adherence and Engagement: Predicting Non-Adherence and Dropout RisksWebinar:
Patient adherence remains a significant challenge in clinical research and medical practice, affecting drug development, healthcare costs, and…
News
Cognivia Named Finalist for the Award of ‘Scale-up de l’Année – Scale-up of the Year 2022’
We are proud to be a finalist for the award of ‘Scale-up de l’Année – Scale-up of the…